Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Information source: Handok Pharmaceuticals Co., Ltd.
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: N/A
Status: Recruiting
Sponsored by: Handok Pharmaceuticals Co., Ltd.
Summary
This is a prospective, non-comparative, open, observational study.
Clinical Details
Study design: Time Perspective: Prospective
Primary outcome: Asthma control day
Secondary outcome: Morning peak expiratory flowasthma exacerbation The number of Reliever use Asthma symptom score Number of Participants with Adverse Events
Eligibility
Minimum age: 6 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Children who is prescribed with ciclesonide for asthma
Exclusion Criteria:
- Subjects with contraindications to ciclesonide use
- Subjects with clinically relevant concomitant disease that could compromise the
patient's safety should not be included in this study.
Locations and Contacts
Handok Pharmaceuticals, Seoul, Korea, Republic of; Recruiting
soo hyun yoon, Phone: 82-2-527-5151, Email: soohyun.yoon@handok.com
young yull Koh, Principal Investigator
Additional Information
Starting date: July 2010
Last updated: September 20, 2011
|
